Literature for simeprevir (S29.001 inhibitor)

(Topics flags: S Structure, M Mutation, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2015
1. Verbinnen,T., Fevery,B., Vijgen,L., Jacobs,T., De Meyer,S. and Lenz,O.
   In vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants
   Antimicrob Agents Chemother59, 7548-7557. PubMed  Europe PubMed DOI  I
2014
2. Ehret,R., Neifer,S., Walter,H., Baumgarten,A. and Obermeier,M.
   Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
   J Int AIDS Soc17, 19741-19741. PubMed  Europe PubMed  M  I
2012
3. Kazmierski,W.M., Hamatake,R., Duan,M., Wright,L.L., Smith,G.K., Jarvest,R.L., Ji,J.J., Cooper,J.P., Tallant,M.D., Crosby,R.M., Creech,K., Wang,A., Li,X., Zhang,S., Zhang,Y.K., Liu,Y., Ding,C.Z., Zhou,Y., Plattner,J.J., Baker,S.J., Bu,W. and Liu,L.
   Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants
   J Med Chem55, 3021-3026. PubMed  Europe PubMed DOI  I
4. Tanwar,S., Trembling,P.M. and Dusheiko,G.M.
   TMC435 for the treatment of chronic hepatitis C
   Expert Opin Investig Drugs21, 1193-1209. PubMed  Europe PubMed DOI  I
5. Xue,W., Pan,D., Yang,Y., Liu,H. and Yao,X.
   Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435
   Antiviral Res93, 126-137. PubMed  Europe PubMed DOI  I
2011
6. Gottwein,J.M., Scheel,T.K., Jensen,T.B., Ghanem,L. and Bukh,J.
   Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
   Gastroenterology141, 1067-1079. PubMed  Europe PubMed DOI  I
2010
7. Bae,A., Sun,S.C., Qi,X., Chen,X., Ku,K., Worth,A., Wong,K.A., Harris,J., Miller,M.D. and Mo,H.
   Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors
   Antimicrob Agents Chemother54, 5288-5297. PubMed  Europe PubMed DOI  I
8. Cummings,M.D., Lindberg,J., Lin,T.I., de Kock,H., Lenz,O., Lilja,E., Fellander,S., Baraznenok,V., Nystrom,S., Nilsson,M., Vrang,L., Edlund,M., Rosenquist,A., Samuelsson,B., Raboisson,P. and Simmen,K.
   Inside cover: Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target
   Angew Chem Int Ed Engl49, 1510-1510. PubMed  Europe PubMed DOI  S  I
9. Cummings,M.D., Lindberg,J., Lin,T.I., de Kock,H., Lenz,O., Lilja,E., Fellander,S., Baraznenok,V., Nystrom,S., Nilsson,M., Vrang,L., Edlund,M., Rosenquist,A., Samuelsson,B., Raboisson,P. and Simmen,K.
   Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target
   Angew Chem Int Ed Engl49, 1652-1655. PubMed  Europe PubMed DOI  S  I
2009
10. Lin,T.I., Lenz,O., Fanning,G., Verbinnen,T., Delouvroy,F., Scholliers,A., Vermeiren,K., Rosenquist,A., Edlund,M., Samuelsson,B., Vrang,L., de Kock,H., Wigerinck,P., Raboisson,P. and Simmen,K.
    In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor
    Antimicrobial Agents Chemother53, 1377-1385. PubMed  Europe PubMed DOI  I
11. Tsantrizos,Y.S.
    TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection
    Curr Opin Investig Drugs10, 871-881. PubMed  Europe PubMed  I
2008
12. Liang,Y., Ishida,H., Lenz,O., Lin,T.I., Nyanguile,O., Simmen,K., Pyles,R.B., Bourne,N., Yi,M., Li,K. and Lemon,S.M.
    Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors
    Gastroenterology135, 1710-1718. PubMed  Europe PubMed DOI  I
13. Raboisson,P., de Kock,H., Rosenquist,A., Nilsson,M., Salvador-Oden,L., Lin,T.I., Roue,N., Ivanov,V., Wahling,H., Wickstrom,K., Hamelink,E., Edlund,M., Vrang,L., Vendeville,S., Van de Vreken,W., McGowan,D., Tahri,A., Hu,L., Boutton,C., Lenz,O., Delouvroy,F., Pille,G., Surleraux,D., Wigerinck,P., Samuelsson,B. and Simmen,K.
    Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
    Bioorg Med Chem Lett18, 4853-4858. PubMed  Europe PubMed DOI  I